Add Yahoo as a preferred source to see more of our stories on Google. A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of ...

The American Lung Association today announced the launch of the COPD-OMA trial, a national clinical research effort conducted through its Airways Clinical Research Centers (ACRC). The study will ...

Please provide your email address to receive an email when new articles are posted on . The rise in discussion of ventilation support was due to two articles published in the June issue of CHEST being ...

Chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, affects more than 30 million ...

Please provide your email address to receive an email when new articles are posted on . Less than 40% of the studied veteran cohort were adherent to their inhaled COPD medications. Adherence was found ...

When living with chronic obstructive pulmonary disease (COPD), you can help prevent lung infections by quitting smoking and avoiding irritants such as secondhand smoke and strong scents. It’s ...

Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary ...

SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 diabetes. There was little difference between SGLT2 inhibitors and GLP-1 receptor ...

“Compared to non-CMR recipients, CMR recipients experienced a considerably higher increase in adherence to COPD medications from 2016 to 2017, and findings with data from more recent years are ...

Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...